0000950170-24-001197.txt : 20240103
0000950170-24-001197.hdr.sgml : 20240103
20240103173040
ACCESSION NUMBER: 0000950170-24-001197
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240101
FILED AS OF DATE: 20240103
DATE AS OF CHANGE: 20240103
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: LEONARD JOHN M
CENTRAL INDEX KEY: 0001563584
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37766
FILM NUMBER: 24508332
MAIL ADDRESS:
STREET 1: C/O INTELLIA THERAPEUTICS INC
STREET 2: 40 ERIE STREET, SUITE 130
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
FORMER NAME:
FORMER CONFORMED NAME: LEONARD JOHN M.
DATE OF NAME CHANGE: 20121204
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Intellia Therapeutics, Inc.
CENTRAL INDEX KEY: 0001652130
STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 364785571
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 40 ERIE STREET
STREET 2: SUITE 130
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
BUSINESS PHONE: 857-285-6200
MAIL ADDRESS:
STREET 1: 40 ERIE STREET
STREET 2: SUITE 130
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
4
1
ownership.xml
4
X0508
4
2024-01-01
0001652130
Intellia Therapeutics, Inc.
NTLA
0001563584
LEONARD JOHN M
C/O INTELLIA THERAPEUTICS, INC.
40 ERIE STREET; SUITE 130
CAMBRIDGE
MA
02139
true
true
false
false
President and CEO
false
Common Stock
2024-01-01
4
M
false
7848
A
865709
D
Common Stock
58415
I
By Trust
Restricted Stock Unit
2024-01-01
4
M
false
7848
0
D
2024-01-01
2031-03-02
Common Stock
7848
7850
D
Restricted stock units ("RSUs") convert into common stock on a one-for-one basis.
Shares held by the John M. Leonard 2015 Irrevocable Trust.
On March 3, 2021, the reporting person was granted 31,394 RSUs pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan. Each RSU represents a contingent right to receive one share of the Company's common stock upon vesting, with 25% of the RSU vesting on January 1, 2022 and the remaining awards vesting as to 25% in substantially equal annual installments thereafter.
James Basta, attorney-in-fact
2024-01-03